|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Overruled: No More Dual Pricing
Author(s)Kevin Gopal
European Union-The European Commission’s ban on GlaxoSmith–Kline’s dual pricing policy in Spain halts one of Big Pharma’s attempts to prevent parallel imports in Europe.
Advertisement
Articles in this issue
over 24 years ago
Pharmacies: OTC Price Warsover 24 years ago
One Disease at a Timeover 24 years ago
Overview of the Industry: A World of Opportunitiesover 24 years ago
The Power Shiftover 24 years ago
A Giant Stumblesover 24 years ago
Submergedover 24 years ago
Generic ThreatNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
4
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
5
